» Factor VIII Inhibitor Plasma Negative Control

HEMOSTASIS COAGULATION ROUTINE INHIBITOR NIJMEGEN BETHESDA ASSAYS FVIII INHIBITOR NIJMEGEN BETHESDA CONTROLS

Factor VIII Inhibitor Plasma Negative Control

Nijmegen Bethesda Controls

Factor VIII deficient plasmas without Factor VIII inhibitor.
This plasma can be used for the negative control of the determination of Factor VIII (FVIII) inhibitor according to the Bethesda assays or modified Nijmegen Bethesda assays.

Factor VIII Inhibitor Plasma Negative Control is made from a pool of Factor VIII deficient (<1%) human plasma.
It contains a specific natural inhibitor directed against the activity of Factor VIII (FVIII).

Reference	6-1850-05
Presentation	Vial
Format	25 x 0.5 mL
Quote

Price list, safety data sheets and notices are accessible to our registered customers.

Reference	Presentation	Format	Quote	Product sheet
6-1850-05	Vial	25 x 0.5 mL

Price list, safety data sheets and notices are accessible to our registered customers.

Factor VIII Inhibitor Plasma Negative Control Certificate of analysis

Treatment for hemophilia A consists of injecting the missing Factor VIII by I.V. to prevent or stop the bleeding.
A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.

The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by the Bethesda assay or modified Nijmegen Bethesda and is expressed in BU.
1BU neutralizes 50% of the activity of FVIII for hemophilia A.

- 25 cryotubes x 0.5 mL of frozen plasma

CRYOcheck™ Factor VIII Inhibitor Kit
Factor IX Inhibitor Plasma Negative Control
Factor IX Inhibitor Plasma Weak Control
Factor VIII Inhibitor Plasma
Factor VIII Inhibitor Plasma HCV neg
Factor VIII Inhibitor Plasma Weak Control

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Reactive in liquid form.
	Reactive in lyophilized form.
	Reactive in frozen form.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer
	Distributor.

HEMOSTASIS COAGULATION ROUTINE INHIBITOR NIJMEGEN BETHESDA ASSAYS FVIII INHIBITOR NIJMEGEN BETHESDA CONTROLS